Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - solution injectable en seringue préremplie - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - injektionslösung in einem fertigpen - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 und 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - risankizumabum - injektionslösung im fertigpen - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen; psoriasis-arthritis - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - imlifidasum - pulver für ein konzentrat zur herstellung einer infusionslösung - imlifidasum 11 mg, mannitolum, polysorbatum 80, trometamolum, dinatrii edetas, acidum hydrochloridum, pro vitro corresp. natrium 0.004 mg. - prévention du rejet de greffe suite à la transplantation d’organes solides - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kann als monotherapie oder in kombination mit methotrexat verwendet werden. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Europäische Union - Deutsch - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - arthritis, rheumatoide - immunsuppressiva - kevzara in kombination mit methotrexat (mtx) ist indiziert für die behandlung von mäßig bis stark aktiver rheumatoider arthritis (ra) bei erwachsenen patienten, die haben nur unzureichend beantwortet, oder wer sind intolerant gegenüber einem oder mehreren krankheitsmodifizierende anti-rheumatische drogen (dmards). kevzara kann als monotherapie bei intoleranz gegenüber mtx oder bei behandlung mit mtx angewendet werden.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - tocilizumabum - konzentrat zur herstellung einer infusionslösung - tocilizumabum 80 mg, polysorbatum 80, saccharum, dinatrii phosphas dodecahydricus, natrii dihydrogenophosphas dihydricus, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 1.76 mg. - rheumatoide arthritis. systemische juvenile idiopathische arthritis. polyartikuläre juvenile idiopathische arthritis. zytokinfreisetzungssyndrom. - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - tocilizumabum - konzentrat zur herstellung einer infusionslösung - tocilizumabum 200 mg, polysorbatum 80, saccharum, dinatrii phosphas dodecahydricus, natrii dihydrogenophosphas dihydricus, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 4.43 mg. - rheumatoide arthritis. systemische juvenile idiopathische arthritis. polyartikuläre juvenile idiopathische arthritis. zytokinfreisetzungssyndrom. - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - tocilizumabum - konzentrat zur herstellung einer infusionslösung - tocilizumabum 400 mg, polysorbatum 80, saccharum, dinatrii phosphas dodecahydricus, natrii dihydrogenophosphas dihydricus, aqua ad iniectabile q.s. ad solutionem pro 20 ml corresp. natrium 8.84 mg. - rheumatoide arthritis. systemische juvenile idiopathische arthritis. polyartikuläre juvenile idiopathische arthritis. zytokinfreisetzungssyndrom. - biotechnologika